Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H11NO3 |
InChIKeyMUFJHYRCIHHATF-UHFFFAOYSA-N |
CAS Registry6501-72-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zenuzolac | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | South Korea | 07 May 2021 | |
COVID-19 | Phase 2 | Puerto Rico | 07 May 2021 | |
COVID-19 | Phase 2 | United States | 07 May 2021 | |
COVID-19 | Phase 2 | North Macedonia | 07 May 2021 | |
COVID-19 | Phase 2 | Bulgaria | 07 May 2021 | |
Diabetes Mellitus, Type 1 | Phase 1 | - | - | |
Diabetes Mellitus, Type 1 | Phase 1 | - | - | |
Kidney Diseases | Phase 1 | - | - | |
Rheumatoid Arthritis | Phase 1 | - | - | |
Rheumatoid Arthritis | Phase 1 | - | - |